SecBot SecBot
SECBOTREPLAY Home › Report › REGN

REGN · Christine Poon, a director of Regeneron Pharmaceuticals, filed a Form…

REGENERON PHARMACEUTICALS, INC. · 144 filed Nov 2, 2026 at 17:20 ET

At the news

NEUTRALIMPACT 2/10

144 filed Nov 2, 2026 at 17:20 ET

Christine Poon, a director of Regeneron Pharmaceuticals, filed a Form 144 notice of intent to sell 7,830 shares of common stock with an approximate market value of $7.53 million, to be executed through Goldman Sachs. The shares were acquired through stock option exercises in 2018, 2019, and 2020. This is a routine insider sale by a non-executive director and represents a small fraction of the company's $84.3 billion market cap.

  • Christine Poon, a director, filed Form 144 to sell 7,830 shares of Regeneron common stock.
  • Estimated sale value is approximately $7.53 million based on the filing.
  • Shares were acquired via stock option exercises on January 3, 2018, 2019, and 2020 (2,610 shares each).
  • The sale is planned for execution on or after November 2, 2026 through Goldman Sachs & Co. LLC.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access